NATIONAL MARROW DONOR PROGRAM® (NMDP)/BE THE MATCH®
U.S. TRANSPLANT CENTER PARTICIPATION CRITERIA

NMDP has established Transplant Center Participation Criteria to address the qualification of centers for participation in the NMDP Network. NMDP has also established Standards, policies, procedures, guidelines, protocols, and participation agreements that may impose additional requirements for centers and support laboratories.

In this document, the terms “patient” and “recipient” both refer to the spectrum of individuals who are potential candidates for hematopoietic cell transplantation to individuals who have received a hematopoietic cell product.

FACILITY CHARACTERISTICS

1. Center must be accredited by an organization granted deemed status by Centers for Medicare & Medicaid Services (CMS).

2. Center must use a designated inpatient unit that minimizes the risk of infection.

3. Center must use a designated area for outpatient evaluation and treatment that reduces the risk of transmission of infectious agents and is available 24 hours per day, seven days per week.

4. A program with multiple patient care units that requests to be recognized as a single NMDP center must demonstrate functional unity through shared elements that include:
   a. A medical director who has NMDP responsibilities for all units and serves as the single point of contact for the NMDP on clinical matters;
   b. Standard operating procedures and policies;
   c. Staff training programs.

If the patient care units are located in more than one institution:
   a. At least the primary institution must satisfy all U.S. Transplant Center Participation Criteria, and
   b. The secondary institution(s) must demonstrate evidence of functional unity with the primary institution for at least the past year, and must have performed allogeneic transplants in the past year.

5. Center must have adequate staff, resources, space, equipment, and supplies to perform and manage activities.

6. Centers participating in human subject research must hold a Federalwide Assurance (FWA) filed with the Office for Human Research Protection (OHRP).

PERSONNEL AND TRANSPLANT TEAM

7. Center must designate an NMDP medical director who is a licensed physician qualified by training and experience to perform and/or supervise defined center activities and who:
   a. Is board certified (or non-U.S. specialist certification equivalent) in one or more of the following specialties: Hematology, Immunology, Medical Oncology, or Pediatric Hematology/Oncology. Non-board certified physicians who completed medical training prior to 1985 may serve as the NMDP Medical Director if they have documented experience in the field of hematopoietic progenitor cell transplantation extending over ten years;
   b. Is responsible for search management activities and protecting the safety of the recipient;
c. Has had at least two years of experience, within the past five years, as an attending physician responsible for clinical management of allogeneic transplant recipients in the inpatient and outpatient settings; and
d. Participates annually in educational activities related to the field of hematopoietic cell transplantation (at least one CME credit hour).

8. Center must have at least two attending physicians (including the NMDP medical director) who:
   a. Are licensed physicians;
   b. Are qualified by training and experience in allogeneic hematopoietic cell transplantation. Adequate clinical training in allogeneic cell transplant is defined as a minimum of one year experience in the management of transplant recipients in both the inpatient and outpatient settings;
   c. Provide continuous 12-month coverage for both the inpatient unit and outpatient clinic;
   d. Should be board certified (or non-U.S. specialist equivalent) in one or more of the following specialties: Hematology, Immunology, Medical Oncology, or Pediatric Hematology/Oncology; and
   e. Participate annually in educational activities related to the field of hematopoietic cell transplantation (at least one CME credit hour or non-U.S. equivalent per year).

9. Center must use an experienced team that has performed allogeneic transplants for at least 10 different patients per year. Center must demonstrate that allogeneic recipients achieved survival rates acceptable to the NMDP. A center that performed fewer than 10 allogeneic transplants per year for the past 24 months may qualify as a Low Volume Transplant Center, as described in criterion #44.

10. Centers performing pediatric transplants must use a transplant team trained in the management of pediatric patients.

11. Center must provide daily and emergency coverage by designated transplant coordinator(s), sufficient in number to meet the needs of the center’s activities.

12. Center must have nurses qualified by training and experience in the care of transplant recipients, with the capacity for 1:1 nurse-to-inpatient ratio for acutely ill patients.

13. Center must have sufficient data management personnel to comply with the Center for International Blood and Marrow Transplant Research (CIBMTR) and NMDP data submission requirements.

14. Center personnel must comply with NMDP training requirements, including but not limited to confidentiality training.

15. Center must document staff and volunteer training, continuing education, and continued competency for relevant skills.

**SUPPORT SERVICES**

16. Center must use facilities that are licensed, certified, or accredited in accordance with applicable U.S. federal and state laws and regulations. Additional requirements include:
   a. Laboratory(ies) certified by Centers for Medicare & Medicaid Services (CMS) for clinical laboratory tests required by the NMDP.
b. Laboratory(ies) accredited by the American Society of Histocompatibility and Immunogenetics (ASHI), and/or the College of American Pathologists (CAP) for HLA typing required by NMDP. The laboratory designated by the transplant center is responsible for the final HLA typing of the patient and donor.

c. Laboratory(ies) that can detect CMV infection by quantitative PCR, viral culture, antibody tests, or equivalent and provide results within 72 hours.

d. Laboratory that can count the number of nucleated cells and quantify CD34-positive cells in HPC(A) products.

e. Laboratory(ies) that can confirm ABO grouping and Rh typing of HPC(M) or HPC(A) products, or blood obtained from the donor at the time of collection.

f. Laboratory(ies) that can perform fungal and bacterial cultures on products received.

g. Transfusion service(s) that provides 24-hour blood component support for transplant patients, including irradiated blood components and components suitable for CMV-negative recipients.

17. Center must have access to a person qualified by training and experience in human histocompatibility testing to assist in the selection of unrelated hematopoietic cells or donors.

18. Center must have experienced physicians who provide consultative services in at least the following disciplines: Cardiology, Gastroenterology, Infectious Diseases, Intensive Care, Nephrology, Pathology, Pulmonary Medicine, Psychiatry, Surgery, Transfusion Medicine, and if applicable, Radiation Therapy.

19. Center must have sufficient staff from at least the following services: Dentistry, Dietary, Pharmacy, Physical Therapy, Respiratory Therapy, and Social Services.

20. Center must have prompt technical and operational support for information systems management.

POLICIES AND PROCEDURES

21. Center must maintain written policies and/or procedures to address at least the following:

   a. Donor or cord blood unit selection;
   b. Financial approval;
   c. Infection prevention and control;
   d. Processing ABO incompatible hematopoietic cell products to reduce the risk of hemolysis;
   e. Hematopoietic cell product infusion;
   f. Blood component transfusion to include transfusion of blood components when the donor and recipient are ABO mismatched; and
   g. Education of the patient pre- and post-transplant.

22. Each recipient of hematopoietic cells from the NMDP must be enrolled in a clinical research protocol which is approved by the center’s institutional review board (IRB), or treated according to a written clinical practice guideline.

23. Center must maintain written clinical practice guidelines to address at least the following:

   a. Criteria for patient eligibility;
   b. Patient evaluations;
   c. Preparative regimens for transplantation;
d. Prevention and treatment of graft-versus-host disease;
e. CMV prophylaxis, surveillance and treatment; and
f. Post-transplant care

24. Center must have a quality assurance program designed at minimum to promptly identify, process, report, and prevent, if applicable, the following per NMDP requirements:
   a. Adverse events;
b. Deviations;
c. Complaints;
d. Nonconforming products, materials, or services;
e. Corrective actions and preventive actions

25. Center must maintain relevant records, in accordance with NMDP Standards, to ensure the identification and traceability/trackability of each donor and cellular therapy product and all related samples.
   a. From their initial source, through each processing and testing step to their final disposition; and
   b. From final disposition, through each processing and testing step back to the initial source

26. Center must retain records in accordance with NMDP Standards.

27. Center must participate in the NMDP/CIBMTR Research Sample protocol and the Research Database protocol.

28. Center must maintain a system of strict confidentiality of records that meets or exceeds NMDP requirements for the protection of privacy of potential donors (registry members), donors, patients, and recipients.

**PATIENT ADVOCACY**

29. Center must have policies to ensure timely communication with patients, families, and physicians, including the progress of the search and other treatment options.

30. If a compatible donor or cord blood unit meeting the criteria of the center is not found, the patient must be informed of other options including:
   a. Referral to other NMDP Network Transplant Centers whose criteria for unrelated and related transplants may be different.
   b. Ongoing NMDP search efforts.

31. Center must have a patient advocate who is familiar with the center’s transplant program and issues of unrelated hematopoietic cell transplantation. The center may designate Be The Match Patient and Health Professional Services as their patient advocate.

32. Center must provide required information for the NMDP Transplant Center Directory on an annual basis.
ADMINISTRATIVE

33. Center must comply with NMDP participation requirements, which include NMDP Standards, policies, procedures, guidelines, protocols, and terms of the participation agreement.

34. Center must meet established Continuous Process Improvement (CPI) criteria.

35. Center must provide documentation that it continues to meet NMDP participation requirements on an annual basis.

36. Center must have readily available access to the Internet through which search results, daily reports, vital information, transplant dates, and data are exchanged with the NMDP.

37. Center must complete and submit NMDP and CIBMTR data forms as required.

38. Center must assume financial responsibility for services requested by the center and rendered by the NMDP.

39. Center must maintain adequate professional and general liability insurance coverage, as required in the participation agreement.

40. Center must promptly report to the NMDP any significant changes in personnel (Including but not limited to the medical director and coordinator), facilities, accreditations, or support services.

APPLICANT CENTERS

At the time of initial application, applicant center must meet the following additional criteria:

41. Applicant center must have performed primary allogeneic transplants for at least 10 different patients per year during the previous 24 months or primary allogeneic transplants for 20 different patients in the last 12 months to qualify as a Transplant Center. Applicant centers that perform allogeneic transplants for fewer than ten different patients per year are eligible to apply as a Low Volume Transplant Center (see Low Volume Transplant Center criterion below).

42. Applicant center must submit a "Hematopoietic Stem Cell Transplant History" Form documenting all allogeneic transplants for the previous 24 months, to include the day +100 status for each patient. Experience must demonstrate that applicant center achieved appropriate allogeneic recipient survival rates.

43. Applicant center’s transplant team (including at least one attending physician and a majority of the inpatient and outpatient nurses) must have performed allogeneic transplants at the center for at least the past 12 months.

LOW VOLUME TRANSPLANT CENTERS

44. Applicant or existing NMDP Network Transplant Centers that performed allogeneic transplants for fewer than 10 different patients per year for the previous 24 months may be eligible to participate as Low Volume Transplant Centers, and must have performed at least one allogeneic transplant per year for the past two years. Low Volume Transplant Centers must demonstrate their ability to provide access to unrelated transplants for patients facing barriers that may not be addressed by current NMDP Network Transplant Centers.

NMDP may, in its discretion, approve deviations from these Criteria on a case-by-case basis upon demonstration by the Center of extenuating circumstances.